CML drug combo aims for Treatment-Free remission, but trial stalls
Disease control
Terminated
This phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small…
Phase: PHASE3 • Sponsor: Sarit Assouline • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC